Data protection Impressum

Investment

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (May 2025)

28 May 2025

Western Switzerland is rapidly becoming a hotspot for biomanufacturing and life sciences companies, thanks to its strong infrastructure, skilled talent, and business-friendly policies. Yassin Nahi, GGBa (Greater Geneva Bern area) Life Science Director, shares how the region's research hubs, academic institutions, and regulatory support make it an ideal location for companies in this sector.

Why Western Switzerland for Biomanufacturing and Life Sciences Companies: an interview with expert Yassin Nahi

With a CHF 13 million investment, Mestel has opened a cutting-edge facility in Rossens to boost production of high-end rubber watch straps and smart wearable components for the luxury industry.

Mestel inaugurates CHF 13 million high-tech facility in the canton of Fribourg

26 May 2025

Inaugurated in May 2025, the PULSE Innovation Center in Cheseaux-sur-Lausanne is emerging as a flagship site for life sciences and high-tech companies in Western Switzerland, offering modular infrastructure, shared services, and a unique environment for collaboration and growth.

PULSE, a new era for innovation in Western Switzerland

21 May 2025

Nestlé has announced a strategic transformation of its global R&D operations, including enhanced expertise in biotechnology and the launch of a new deep tech center in Orbe, in the canton of Vaud. These changes aim to strengthen the company’s innovation pipeline while increasing operational efficiency.

Nestlé to boost biotech and deep tech capabilities with new R&D center in Orbe

19 May 2025

The latest edition of the Swiss Biotech Report underscores the continued growth and resilience of Switzerland’s biotech sector, attributing success to strong international collaborations and innovative advancements that promise to reshape healthcare worldwide.

The Swiss biotech industry: building resilience through global alliances

6 May 2025

Burgdorf-based medtech Ypsomed has announced the sale of its diabetes care business to TecMed AG for up to CHF 420 million. The move marks a significant strategic shift, positioning Ypsomed as a pure-play provider of self-injection systems for pharmaceutical and biotech partners worldwide.

Bern-based Ypsomed pivots with CHF 420 million diabetes unit sale to TecMed

23 April 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2025)

23 April 2025

From clinical research to international leadership, Incyte’s steady growth in Western Switzerland showcases the region’s strength in biopharmaceutical innovation.

Incyte, a key player in Western Switzerland’s biopharmaceutical innovation landscape

Toblerone strengthens its Swiss roots with CHF 65 million investment in Bern

14 April 2025

1 2 3 4 5 … 19